Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

Dupilumab shows significant efficacy in reducing itch and hives in CSU patients unresponsive to antihistamines. The CUPID A and CUPID C trials reported a two-thirds reduction in itch and urticaria ...